Boston Scientific Stock

Boston Scientific EBIT

The EBIT of Boston Scientific (BSX) as of Aug 21, 2026 is 3.97 B USD. In the previous year, EBIT was 2.64 B USD — a change of 50.70% (higher).

EBIT

3.97 BUSD

YoY

50.70%

Last updated:

In 2026, Boston Scientific's EBIT was 3.97 B USD, a 50.70% increase from the 2.64 B USD EBIT recorded in the previous year.

The Boston Scientific EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2023
2.18 base
Jan 1, 2024
2.64 base
Jan 1, 2025
3.97 base
Jan 1, 2026 (e)
3.20 base
Jan 1, 2027 (e)
3.34 base
Jan 1, 2028 (e)
3.57 base
Jan 1, 2029 (e)
3.83 base
Jan 1, 2030 (e)
4.22 base
YEAREBIT (B USD)
2030 est 4.22
2029 est 3.83
2028 est 3.57
2027 est 3.34
2026 est 3.20
2025 3.97
2024 2.64
2023 2.18
2022 1.82
2021 1.92
2020 0.60
2019 1.13
2018 1.74
2017 1.16
2016 0.41
2015 0.79
2014 0.85
2013 0.87
2012 0.99
2011 1.12
2010 1.07
2009 1.30
2008 1.30
2007 1.18
2006 1.24
Access this data via the Eulerpool API

Boston Scientific Revenue

Boston Scientific Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
14.24 B USD
2.18 B USD
1.59 B USD
Jan 1, 2024
16.75 B USD
2.64 B USD
1.85 B USD
Jan 1, 2025
20.07 B USD
3.97 B USD
2.89 B USD
Jan 1, 2026 (e)
21.35 B USD
3.20 B USD
4.90 B USD
Jan 1, 2027 (e)
22.29 B USD
3.34 B USD
5.08 B USD
Jan 1, 2028 (e)
23.80 B USD
3.57 B USD
5.59 B USD
Jan 1, 2029 (e)
25.51 B USD
3.83 B USD
6.14 B USD
Jan 1, 2030 (e)
28.15 B USD
4.22 B USD
6.97 B USD

Boston Scientific Margins

Boston Scientific stock margins

The Boston Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boston Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boston Scientific.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
62.02 %
15.32 %
11.19 %
Jan 1, 2024
61.31 %
15.73 %
11.07 %
Jan 1, 2025
69.01 %
19.78 %
14.38 %
Jan 1, 2026 (e)
69.01 %
15.01 %
22.95 %
Jan 1, 2027 (e)
69.01 %
15.01 %
22.80 %
Jan 1, 2028 (e)
69.01 %
15.01 %
23.48 %
Jan 1, 2029 (e)
69.01 %
15.01 %
24.09 %
Jan 1, 2030 (e)
69.01 %
15.01 %
24.77 %

Boston Scientific Stock analysis

What does Boston Scientific do? Boston Scientific Corp. is a global medical technology company specializing in the development and manufacturing of innovative solutions for medical challenges and needs. The company was founded in 1979 and has since been dedicated to meeting the individual needs of patients and medical professionals with innovative products. The history of Boston Scientific began in the 1960s when French engineer Jean-Marc Simon started developing pacemakers at the University of Minnesota. In 1969, Medtronic acquired Simon's pacemaker development, leading to the founding of Boston Scientific. From the beginning, the company focused on the production of cardiovascular implants, including pacemakers, implanted defibrillators, and stents. In the following years, the company achieved continued growth through acquisitions of competitors and advancements in research and development, particularly in the field of minimally invasive procedures. Today, Boston Scientific is a globally leading provider of innovative medical devices and solutions used in various areas of healthcare. Boston Scientific's business model is based on meeting the needs of patients, medical professionals, and healthcare policymakers in order to improve healthcare. The company works closely with doctors, hospitals, nursing facilities, and research institutions to continuously develop innovative solutions for various diseases and conditions. Boston Scientific has five business segments: Cardiovascular Systems, Interventional Oncology and Neuromodulation, Urology and Women's Health, Medical Oncology, and Endoscopy. The Cardiovascular Systems segment includes products and solutions for cardiovascular surgery, including pacemakers, implanted defibrillators, and catheters. The company is also involved in endovascular surgery, offering innovative stent and catheter systems for the treatment of aneurysms and arterial occlusive disease. The Interventional Oncology and Neuromodulation segment includes solutions for the minimally invasive treatment of cancer and chronic pain through catheter and implant systems. For example, Boston Scientific offers intensity-controlled radiofrequency ablation and neuromodulation procedures. The Urology and Women's Health segment includes products for the treatment and diagnosis of urogenital system disorders, including incontinence, urinary incontinence, and genital diseases. Boston Scientific offers innovative solutions for women, such as the treatment of urinary incontinence or the removal of uterine fibroids. The Medical Oncology segment includes products for the diagnosis and treatment of cancer, including in vitro diagnostics and novel treatments such as chemotherapy delivery technology. The Endoscopy segment includes endoscopic solutions, including the diagnosis and therapy of digestive tract, chest, and lung disorders. Boston Scientific's product portfolio is diverse and includes numerous innovative medical devices and systems designed to meet the needs of patients and medical professionals. Some of the notable products of the company include: - The Implantable Cardioverter-Defibrillator (ICD) is an innovative device that can treat heart rhythm disorders through the use of a remote control. - Drug-Eluting Stents are stents that deliver medication directly at the site of narrowing, promoting blood flow and helping to keep the artery open. - The Synergy is a top-of-the-line stent that has both a lower mortality rate and a higher success rate than conventional stents. - The Venus-EP Steerable Sheath is an advanced catheter that allows physicians unique navigation within the heart chambers. - The Precision is a catheter that sends impulses to the heart for the diagnosis and treatment of atrial fibrillation. - The Transcend is a pacemaker that combines traditional pacemaker function with a sensor that actively supports the patient during physical activity. - The Symphion is an innovative system for laparoscopic surgery that enables minimally invasive surgical procedures in women. In conclusion, Boston Scientific Corp. is a globally leading provider of innovative medical devices and solutions that run like a common thread through its various business segments. With a significant focus on research and development, the company offers a wide range of products to ensure that patients worldwide have access to innovative medical care. Through pioneering innovations, the development of new technologies, and collaboration with medical professionals, Boston Scientific will continue to defend its position as a leading provider of medical solutions worldwide. Boston Scientific is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Boston Scientific's EBIT

Boston Scientific's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Boston Scientific's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Boston Scientific's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Boston Scientific’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Boston Scientific stock

EBIT of Boston Scientific is 3.97 B USD in 2026.

EBIT of Boston Scientific changed from 2.64 B USD to 3.97 B USD, representing a 50.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Boston Scientific since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Boston Scientific historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Boston Scientific

All Key Metrics — Boston Scientific